Safety and Immunogenicity of mRNA-1653, a Combined Human Metapneumovirus (hMPV) and Parainfluenza Virus Type 3 (PIV3) Vaccine, in Healthy Adults, and Children 12 to 59 Months of Age With Serologic Evidence of Prior Exposure

Human Metapneumovirus and Human Parainfluenza Infection Clinical Trial

Official title: A Phase 1b, Randomized, Observer-Blind, Placebo-Controlled, Dose Ranging Trial to Evaluate the Safety and Immunogenicity of mRNA-1653, a Combined Human Metapneumovirus (hMPV) and Parainfluenza Virus Type 3 (PIV3) Vaccine When Administered to Adults, and to Children 12 to 59 Months of Age With Serologic Evidence of Prior Exposure

Status Completed

Clinical Trial Summary

This clinical study will assess the safety and immunogenicity of 2 dose levels of mRNA-1653, a combined human metapneumovirus and human parainfluenza virus type 3 vaccine, in healthy adults (18 to 49 years of age) and 2 dose levels in children (12 to 59 months of age) with serologic evidence of prior exposure. The safety profile of the adult cohort will permit enrollment of the pediatric cohort.

Clinical Trial Description

n/a

Related Conditions & MeSH terms

• Human Metapneumovirus and Human Parainfluenza Infection
• Infections
• Paramyxoviridae Infections

• NCT number: NCT04144348
• Study type: Interventional
• Source: ModernaTX, Inc.
• Status: Completed
• Phase: Phase 1
• Start date: November 4, 2019
• Completion date: December 20, 2022